{"name": "Sanofi Aventis",
 "permalink": "sanofi-aventis-2",
 "crunchbase_url": "http://www.crunchbase.com/company/sanofi-aventis-2",
 "homepage_url": "http://en.sanofi-aventis.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2004,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "biopharm",
 "alias_list": "",
 "email_address": "",
 "phone_number": "33 (0)1 53 77 40 00",
 "description": "Drug Development",
 "created_at": "Tue Jul 28 22:40:35 UTC 2009",
 "updated_at": "Fri Aug 12 18:46:48 UTC 2011",
 "overview": "\u003Cp\u003ESanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions.  Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).\u003C/p\u003E\n\n\u003Cp\u003ESanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2008, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       119],
      "assets/images/resized/0005/4534/54534v3-max-150x150.png"],
     [[150,
       119],
      "assets/images/resized/0005/4534/54534v3-max-250x250.png"],
     [[150,
       119],
      "assets/images/resized/0005/4534/54534v3-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": true,
    "title": "Vice President, Diabetes US",
    "person":
     {"first_name": "Michelle",
      "last_name": "Baron",
      "permalink": "michelle-baron",
      "image": null}},
   {"is_past": true,
    "title": "Senior Medical Director, Metabolism",
    "person":
     {"first_name": "Noah",
      "last_name": "Rosenberg",
      "permalink": "noah-rosenberg",
      "image": null}},
   {"is_past": true,
    "title": "Vice President, Metabolism Medical Unit",
    "person":
     {"first_name": "Michelle",
      "last_name": "Baron",
      "permalink": "michelle-baron",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [{"funding_round":
     {"round_code": "unattributed",
      "source_url": "http://www.finsmes.com/2010/10/regulus-therapeutics-receives-10m.html",
      "source_description": "Regulus Therapeutics Receives $10M Equity Investment from Sanofi-Aventis",
      "raised_amount": 10000000.0,
      "raised_currency_code": "USD",
      "funded_year": 2010,
      "funded_month": 10,
      "funded_day": 28,
      "company":
       {"name": "Regulus Therapeutics",
        "permalink": "regulus-therapeutics",
        "image":
         {"available_sizes":
           [[[150,
              33],
             "assets/images/resized/0009/1448/91448v1-max-150x150.png"],
            [[203,
              45],
             "assets/images/resized/0009/1448/91448v1-max-250x250.png"],
            [[203,
              45],
             "assets/images/resized/0009/1448/91448v1-max-450x450.png"]],
          "attribution": null}}}},
   {"funding_round":
     {"round_code": "unattributed",
      "source_url": "http://www.finsmes.com/2012/01/warp-drive-bio-raises-125m.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
      "source_description": "Warp Drive Bio Raises $125M",
      "raised_amount": 125000000.0,
      "raised_currency_code": "USD",
      "funded_year": 2012,
      "funded_month": 1,
      "funded_day": 11,
      "company":
       {"name": "Warp Drive Bio",
        "permalink": "warp-drive-bio",
        "image":
         {"available_sizes":
           [[[150,
              42],
             "assets/images/resized/0016/9776/169776v1-max-150x150.png"],
            [[250,
              71],
             "assets/images/resized/0016/9776/169776v1-max-250x250.png"],
            [[352,
              100],
             "assets/images/resized/0016/9776/169776v1-max-450x450.png"]],
          "attribution": null}}}},
   {"funding_round":
     {"round_code": "unattributed",
      "source_url": "http://www.masshightech.com/stories/2012/02/06/daily12-Rib-X-lands-3M-milestone-pay-from-Sanofi-deal.html",
      "source_description": "Rib-X lands $3M milestone pay from Sanofi deal",
      "raised_amount": 3000000.0,
      "raised_currency_code": "USD",
      "funded_year": 2012,
      "funded_month": 2,
      "funded_day": 7,
      "company":
       {"name": "Rib-X Pharmaceuticals",
        "permalink": "rib-x-pharmaceuticals",
        "image":
         {"available_sizes":
           [[[150,
              49],
             "assets/images/resized/0004/1688/41688v1-max-150x150.png"],
            [[250,
              82],
             "assets/images/resized/0004/1688/41688v1-max-250x250.png"],
            [[282,
              93],
             "assets/images/resized/0004/1688/41688v1-max-450x450.png"]],
          "attribution": null}}}}],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 500000000.0,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://online.wsj.com/article/SB123979301485720613.html",
    "source_description": "Sanofi to Buy BiPar Sciences ",
    "acquired_year": 2009,
    "acquired_month": 4,
    "acquired_day": 15,
    "company":
     {"name": "BiPar Sciences",
      "permalink": "bipar-sciences",
      "image":
       {"available_sizes":
         [[[140,
            62],
           "assets/images/resized/0004/2189/42189v1-max-150x150.png"],
          [[140,
            62],
           "assets/images/resized/0004/2189/42189v1-max-250x250.png"],
          [[140,
            62],
           "assets/images/resized/0004/2189/42189v1-max-450x450.png"]],
        "attribution": null}}},
   {"price_amount": 770000000.0,
    "price_currency_code": "USD",
    "term_code": "stock",
    "source_url": "http://www.fiercebiotech.com/story/sanofi-snaps-indias-shantha-784m/2009-07-27?utm_medium=rss\u0026utm_source=rss\u0026cmp-id=OTC-RSS-FB0",
    "source_description": "Sanofi snaps up India's Shantha for $784M",
    "acquired_year": 2009,
    "acquired_month": 7,
    "acquired_day": 27,
    "company":
     {"name": "Shantha Biotechnics",
      "permalink": "shantha-biotechnics",
      "image":
       {"available_sizes":
         [[[150,
            24],
           "assets/images/resized/0005/4537/54537v1-max-150x150.jpg"],
          [[250,
            40],
           "assets/images/resized/0005/4537/54537v1-max-250x250.jpg"],
          [[429,
            69],
           "assets/images/resized/0005/4537/54537v1-max-450x450.jpg"]],
        "attribution": null}}},
   {"price_amount": 4000000000.0,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://www.reuters.com/article/2009/07/30/us-sanofi-merck-idUSTRE56T16C20090730",
    "source_description": "Sanofi buys rest of Merial from Merck for $4 billion",
    "acquired_year": 2009,
    "acquired_month": 7,
    "acquired_day": 13,
    "company":
     {"name": "Merial Limited",
      "permalink": "merial-limited",
      "image":
       {"available_sizes":
         [[[84,
            70],
           "assets/images/resized/0006/3115/63115v2-max-150x150.jpg"],
          [[84,
            70],
           "assets/images/resized/0006/3115/63115v2-max-250x250.jpg"],
          [[84,
            70],
           "assets/images/resized/0006/3115/63115v2-max-450x450.jpg"]],
        "attribution": null}}},
   {"price_amount": 635000000.0,
    "price_currency_code": "USD",
    "term_code": "cash_and_stock",
    "source_url": "http://www.fiercebiotech.com/story/spree-sanofi-scoops-targegen-635m-deal/2010-06-30?utm_medium=rss\u0026utm_source=rss",
    "source_description": "On a spree, Sanofi scoops up TargeGen in $635M dea  Read more: On a spree, Sanofi scoops up TargeGen in $635M deal",
    "acquired_year": 2010,
    "acquired_month": 6,
    "acquired_day": 30,
    "company":
     {"name": "TargeGen",
      "permalink": "targegen",
      "image":
       {"available_sizes":
         [[[113,
            42],
           "assets/images/resized/0014/9238/149238v1-max-150x150.jpg"],
          [[113,
            42],
           "assets/images/resized/0014/9238/149238v1-max-250x250.jpg"],
          [[113,
            42],
           "assets/images/resized/0014/9238/149238v1-max-450x450.jpg"]],
        "attribution": null}}},
   {"price_amount": 20000000000.0,
    "price_currency_code": "USD",
    "term_code": "cash",
    "source_url": "http://www.masshightech.com/stories/2011/02/14/daily28-Sanofi-paying-20B---and-then-some---for-Genzyme.html",
    "source_description": "Sanofi paying $20B - and then some - for Genzyme",
    "acquired_year": 2011,
    "acquired_month": 2,
    "acquired_day": 16,
    "company":
     {"name": "Genzyme",
      "permalink": "genzyme",
      "image":
       {"available_sizes":
         [[[150,
            50],
           "assets/images/resized/0011/9036/119036v1-max-150x150.png"],
          [[155,
            52],
           "assets/images/resized/0011/9036/119036v1-max-250x250.png"],
          [[155,
            52],
           "assets/images/resized/0011/9036/119036v1-max-450x450.png"]],
        "attribution": null}}}],
 "offices":
  [{"description": "",
    "address1": "174 avenue de France",
    "address2": "",
    "zip_code": "75635",
    "city": "Paris",
    "state_code": null,
    "country_code": "FRA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes",
    "stoned_year": 2009,
    "stoned_month": 10,
    "stoned_day": 21,
    "source_url": "http://en.sanofi-aventis.com/press/press_releases/2009/ppc_26601.asp",
    "source_text": "",
    "source_description": "Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "Sanofi ejects two R\u0026D sites, forges $2.2B pact with Covance",
    "stoned_year": 2010,
    "stoned_month": 9,
    "stoned_day": 30,
    "source_url": "http://www.fiercebiotech.com/story/sanofi-ejects-two-r-d-sites-forges-2-2b-pact-covance/2010-09-30?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Sanofi ejects two R\u0026D sites, forges $2.2B pact with Covance",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "Sanofi raises big loan as it plots Genzyme buyout strategy",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 20,
    "source_url": "http://www.fiercebiotech.com/story/regulators-green-light-sanofis-18-5b-genzyme-bid/2010-10-20?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Sanofi raises big loan as it plots Genzyme buyout strategy",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "Report: Sanofi readies $20B deal package for Genzyme",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 14,
    "source_url": "http://www.fiercebiotech.com/story/report-sanofi-readies-20b-deal-package-genzyme/2011-01-14?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Report: Sanofi readies $20B deal package for Genzyme",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "Sanofi, Genzyme agree on deal structure",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 31,
    "source_url": "http://www.fiercepharma.com/story/reuters-sanofi-genzyme-agree-deal-structure/2011-01-31",
    "source_text": "",
    "source_description": "Sanofi, Genzyme agree on deal structure",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "Genzyme Corp. officially announced the long-awaited approval of its sale to French pharmaceutical giant sanofi-aventis for approximately $20 billion in cash",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 16,
    "source_url": "http://www.masshightech.com/stories/2011/02/14/daily28-Sanofi-paying-20B---and-then-some---for-Genzyme.html",
    "source_text": null,
    "source_description": "Sanofi paying $20B - and then some - for Genzyme",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "Sanofi finally nails $20B+ deal to buy Genzyme\r\n",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 16,
    "source_url": "http://www.fiercebiotech.com/story/sanofi-finally-nails-20b-deal-buy-genzyme/2011-02-16?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Sanofi finally nails $20B+ deal to buy Genzyme",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "Sanofi-Aventis Poised to Purchase Additional Stake in Zentiva",
    "stoned_year": 2009,
    "stoned_month": null,
    "stoned_day": null,
    "source_url": "http://www.invest-iq.com/Belviport-exits-Zentiva",
    "source_text": null,
    "source_description": "Sanofi-Aventis Poised to Purchase Additional Stake in Zentiva",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "J\u0026T will sale the shares of Zentiva",
    "stoned_year": 2009,
    "stoned_month": 2,
    "stoned_day": 2,
    "source_url": "http://www.invest-iq.com/J%2526T-divests-Zentiva-to-Sanofi-Aventis",
    "source_text": null,
    "source_description": "J\u0026T will sale the shares of Zentiva",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "Sanofi terminates $375M Metabolex diabetes deal",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 6,
    "source_url": "http://www.fiercebiotech.com/story/sanofi-terminates-375m-metabolex-diabetes-deal/2011-05-06?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Sanofi terminates $375M Metabolex diabetes deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}},
   {"description": "has simplified its name to Sanofi",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 9,
    "source_url": "http://www.masshightech.com/stories/2011/05/09/daily6-Sanofi-drops-aventis-name.html",
    "source_text": null,
    "source_description": "Sanofi drops aventis name",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Sanofi Aventis",
      "permalink": "sanofi-aventis-2"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}